These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34830633)

  • 41. Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.
    Tanratana P; Ellery P; Westmark P; Mast AE; Sheehan JP
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):266-274. PubMed ID: 29097362
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor.
    Zhong D; Bajaj MS; Schmidt AE; Bajaj SP
    J Biol Chem; 2002 Feb; 277(5):3622-31. PubMed ID: 11723140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.
    Matsumoto T; Nogami K; Shima M
    Int J Hematol; 2017 Feb; 105(2):174-183. PubMed ID: 27730530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.
    Senthil M; Chaudhary P; Smith DD; Ventura PE; Frankel PH; Pullarkat V; Trisal V
    Thromb Res; 2014 Jul; 134(1):165-8. PubMed ID: 24830901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interactions between residues 2228-2240 within factor VIIIa C2 domain and factor IXa Gla domain contribute to propagation of clot formation.
    Soeda T; Nogami K; Ogiwara K; Shima M
    Thromb Haemost; 2011 Nov; 106(5):893-900. PubMed ID: 21947241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform.
    Katayama H; Matsumoto T; Wada H; Fujimoto N; Toyoda J; Abe Y; Ohishi K; Yamashita Y; Ikejiri M; Habe K; Katayama N
    Clin Appl Thromb Hemost; 2018 Oct; 24(7):1170-1176. PubMed ID: 29439640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Sardinian Family with Factor XI Deficiency.
    Barcellona D; Favuzzi G; Vannini ML; Piras SM; Ruberto MF; Grandone E; Marongiu F
    Hamostaseologie; 2019 Nov; 39(4):398-403. PubMed ID: 31364091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
    Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
    Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
    Lu Q; Yang L; Manithody C; Wang X; Rezaie AR
    Biochemistry; 2015 Jun; 54(24):3814-21. PubMed ID: 26023895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Collaborative study on assays of activated FIX (FIXa). On behalf of the factor VIII and factor IX subcommittee of the ISTH. International Society on Thrombosis and Haemostasis.
    Gray E; Walker D; Heath A; Barrowcliffe TW
    Thromb Haemost; 1996 Dec; 76(6):1114-7. PubMed ID: 8972040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia.
    Kristensen AT; Wiinberg B; Jessen LR; Andreasen E; Jensen AL
    J Vet Intern Med; 2008; 22(1):140-7. PubMed ID: 18289301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
    Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
    Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access.
    LeSar CJ; Merrick HW; Smith MR
    J Am Coll Surg; 1999 Jul; 189(1):73-9; discussion 79-81. PubMed ID: 10401743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rotation thromboelastometry and the hypercoagulable state in Cushing's syndrome.
    Coelho MC; Vieira Neto L; Kasuki L; Wildemberg LE; Santos CV; Castro G; Gouvêa G; Veloso OC; Gadelha T; Gadelha MR
    Clin Endocrinol (Oxf); 2014 Nov; 81(5):657-64. PubMed ID: 24815846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study.
    Marongiu F; Ntoukas DM; Barberini L; Ruberto MF; Piras MS; Conti M; Di Martino ML; Mura M; Marongiu S; Vannini ML; Lillu M; Piras M; Fanni D; Fenu L; Porcu C; Barcellona D; Faa G; Congiu T
    J Public Health Res; 2021 May; 10(4):. PubMed ID: 34036778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clot waveform analysis: Where do we stand in 2017?
    Sevenet PO; Depasse F
    Int J Lab Hematol; 2017 Dec; 39(6):561-568. PubMed ID: 28876509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis.
    Plautz WE; Sekhar Pilli VS; Cooley BC; Chattopadhyay R; Westmark PR; Getz T; Paul D; Bergmeier W; Sheehan JP; Majumder R
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):816-828. PubMed ID: 29419409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity, folding, misfolding, and aggregation in vitro of the naturally occurring human tissue factor mutant R200W.
    Wiréhn J; Carlsson K; Herland A; Persson E; Carlsson U; Svensson M; Hammarström P
    Biochemistry; 2005 May; 44(18):6755-63. PubMed ID: 15865421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of thrombelastography in primary total knee and total hip replacement: a prospective 87 patients study.
    Wang C; Liu Q; Sun L; Dai G
    Blood Coagul Fibrinolysis; 2019 Sep; 30(6):281-290. PubMed ID: 31369408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.